Klinikum Esslingen GmbH
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (C16)
At Klinikum Esslingen, investigators are focusing on improving outcomes for the most vulnerable newborns. The research examines innovative respiratory support strategies for preterm infants born between 23 and 28 weeks, aiming to reduce complications such as retinopathy of prematurity and bronchopulmonary dysplasia. A parallel effort evaluates the safety of new ventilator algorithms that automatically adjust oxygen delivery.
- Closed‑loop oxygen control versus manual adjustment in extremely low‑birth‑weight infants
- Evaluation of long‑term neurodevelopmental outcomes after novel ventilation
- Assessment of respiratory morbidity in infants receiving automated FiO₂ regulation
The site participates in 74 active trials with a team of 20 investigators, reflecting a strong commitment to neonatal care.
Female Urogenital Diseases and Pregnancy Complications (C13)
The department of women’s health at Klinikum Esslingen conducts extensive research on cancers that affect women, especially breast cancer and ovarian cancer. Trials test novel antibody‑drug conjugates, immunotherapy combinations, and targeted agents to improve survival after surgery and chemotherapy. Some studies also explore hormonal therapies for hormone‑receptor‑positive disease.
- Neoadjuvant atezolizumab for triple‑negative breast cancer
- Adjuvant HER2‑targeted therapy in early‑stage disease
- PARP inhibitor plus chemotherapy for high‑grade serous ovarian cancer
- Hormone‑free maintenance strategies for ER‑positive breast cancer
Among the 74 trials, a substantial proportion address female urogenital malignancies, supported by 20 dedicated investigators.
Hemic and Lymphatic Diseases (C15)
Research in the hematology unit of Klinikum Esslingen targets blood‑related malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and various lymphomas. The goal is to identify safer, more effective regimens by combining targeted antibodies, kinase inhibitors, and novel cellular therapies.
- Combination of venetoclax with hypomethylating agents in AML
- BTK inhibitor added to reduced‑dose R‑CHOP for elderly diffuse large B‑cell lymphoma
- CAR‑T cell feasibility in relapsed multiple myeloma
- Novel monoclonal antibodies for chronic lymphocytic leukemia
The site’s portfolio includes multiple trials on hematologic cancers, with 20 investigators contributing to 74 studies overall.
Neoplasms (C04)
Klinikum Esslingen’s oncology program spans a broad spectrum of solid tumors, from non‑small cell lung cancer to gastrointestinal and biliary cancers. Clinical investigations assess precision‑medicine approaches, including ALK and KRAS inhibitors, as well as immunotherapy‑based combinations, to extend survival and improve quality of life.
- ALK‑positive NSCLC targeted therapy with next‑generation inhibitors
- KRAS G12C inhibitor plus pembrolizumab in KRAS‑mutated lung cancer
- Immunotherapy plus chemotherapy in resectable gastric adenocarcinoma
- Adjuvant durvalumab in early‑stage NSCLC after surgery
- FGFR2‑fusion directed therapy for intrahepatic cholangiocarcinoma
Out of the 74 active trials, many focus on advanced solid tumours, reflecting the site’s multidisciplinary expertise.
Respiratory Tract Diseases (C08)
The respiratory research at Klinikum Esslingen concentrates on malignant lung conditions, particularly small‑cell lung cancer and various subtypes of non‑small cell lung cancer. Trials evaluate novel checkpoint inhibitors, antibody‑drug conjugates, and targeted agents to overcome resistance and achieve durable responses.
- Checkpoint inhibitor versus chemotherapy in extensive‑stage SCLC
- Maintenance immunotherapy after definitive chemoradiation for stage III NSCLC
- Antibody‑drug conjugate for PD‑L1‑high NSCLC
- Combination of anti‑angiogenic therapy with immunotherapy in metastatic NSCLC
- Biomarker‑driven arms for EGFR and ROS1 alterations
These lung‑focused studies form a core component of the 74 trials conducted at the site, with a dedicated team of investigators.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 134 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 131 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
- 1AstraZeneca AB4active
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB9trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Esslingen GmbH
lock Showing 1 of 87 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 134 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 25 | Unknown | 2018-06-13 | 2026-03-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.